Genomic medicine and risk prediction across the disease spectrumFootnote

Referees: Prof Jeanine Marnewick, Cape Peninsula University of Technology, Health and Wellness Sciences, Cape Town, South Africa; Prof. Rafael Rangel-Aldao, Biotechnology, Simon Bolivar University, Venezuela

References

• Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448–5
   PubMed Web of Science ®Google Scholar
• Janssens CJW, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008;17:166–73
   PubMed Web of Science ®Google Scholar
• Hood L. Systems biology and P4 medicine: past, present and future. Rambam Maimonides Med J 2013;4:e0012
   PubMedGoogle Scholar
• Myers RH. Huntington’s disease genetics. NeuroRx 2004;1:255–62
   PubMedGoogle Scholar
• Weitzel JN, Blazer KR, Macdonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011;61:327–59
   PubMed Web of Science ®Google Scholar
• Khoury MJ, Berg A, Coates R, et al. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008;27:1600–11
   PubMed Web of Science ®Google Scholar
• Cornel MC, van El CG, Borry P. The challenge of implementing genetic tests with clinical utility while avoiding unsound applications. J Community Genet 2014;5:7–12
   PubMedGoogle Scholar
• Kotze MJ, van Velden DP, Botha K, et al. Pathology-supported genetic testing directed at shared disease pathways for optimized health in later life. Personalized Med 2013;10:497–507
   Web of Science ®Google Scholar
• Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine – payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 2012;15:1162–71
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Michiels S, Zagouri F, et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013;24:647–54
   PubMed Web of Science ®Google Scholar
• Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS One 2009;4:e4346
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimer’s and Huntington’s diseases: shared targets for drug development. Nat Rev Drug Discov 2011;10:853–67
   PubMed Web of Science ®Google Scholar
• Li Y, Huang T, Xiao Y, et al. Prioritising risk pathways of complex human diseases based on functional profiling. Eur J Hum Genet 2013;21:666–72
   PubMed Web of Science ®Google Scholar
• Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet 2012;13:135–45
   PubMed Web of Science ®Google Scholar
• Wagner MJ. Rare-variant genome-wide association studies: a new frontier in genetic analysis of complex traits. Pharmacogenomics 2013;14:413–24
   PubMed Web of Science ®Google Scholar
• Donahue MP, Marchuk DA, Rockman HA. Redefining heart failure: the utility of genomics. J Am Coll Cardiol 2006;48:1289–98
   PubMed Web of Science ®Google Scholar
• Brand A, Brand H, Schulte in den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet 2008;16:5–13
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Van Velden DP, Van Rensburg SJ, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: new insights for clinical application. J Int Fed Clin Chem Lab Med 2009;20:1–15
   Google Scholar
• Kotze MJ, van Rensburg SJ. Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer’s disease. Metab Brain Dis 2012;27:255–66
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Gamieldien J. Challenges, successes and current opportunities in whole exome sequencing. Specialist Forum 2013;13:6–7
   Google Scholar
• Schoeman M, Apffelstaedt JP, Baatjes K, Urban M. Implementation of a breast cancer genetic service in South Africa – lessons learned. S Afr Med J 2013;103:529–33
   PubMedGoogle Scholar
• Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297–303
   PubMed Web of Science ®Google Scholar
• Grant KA, Apffelstaedt JP, Wright C, et al. MammaPrint Prescreen Algorithm (MPA) reduces chemotherapy in patients with early stage breast cancer. S Afr Med J 2013;103:522–6
   PubMedGoogle Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–33
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676–89
   PubMed Web of Science ®Google Scholar
• Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339–47
   PubMed Web of Science ®Google Scholar
• Larsen MJ, Kruse TA, Tan Q, et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 2013;8:e64268
   PubMed Web of Science ®Google Scholar
• Larsen MJ, Thomassen M, Tan Q, et al. RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families. BMC Med Genomics 2014;7:9
   PubMedGoogle Scholar
• Naushad SM, Pavani A, Rupasree Y, et al. Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer. Mol Carcinog 2012;51:32–41
   Google Scholar
• Gracia-Aznarez FJ, Fernandez V, Pita G, et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 2013;8:e55681
   PubMed Web of Science ®Google Scholar
• Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008;14:5913–18
   PubMed Web of Science ®Google Scholar
• Jakubowska A, Gronwald J, Menkiszak J, et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 2007;104:299–308
   PubMed Web of Science ®Google Scholar
• Pepe C, Guidugli L, Sensi E, et al. Methyl group metabolism gene polymorphisms as modifiers of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Res Treat 2007;103:29–36
   PubMed Web of Science ®Google Scholar
• Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011;121:3786–8
   PubMed Web of Science ®Google Scholar
• Glück S, de Snoo F, Peeters J, et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013;139:759–67
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25:5846–53
   PubMed Web of Science ®Google Scholar
• Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 2013;20:3254–8
   PubMed Web of Science ®Google Scholar
• Davis A, Raklamani V. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012;2012:1–10
   Google Scholar
• Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011;22:2687–92
   PubMed Web of Science ®Google Scholar
• Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006;8:R38
   PubMed Web of Science ®Google Scholar
• De Leeneer K, Coene I, Crombez B, et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treat 2012;132:87–95
   PubMed Web of Science ®Google Scholar
• Van der Merwe N, Bouwens CSH, Pienaar R, et al. CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application. Metab Brain Dis 2012;27:319–26
   PubMed Web of Science ®Google Scholar
• Reeves MD, Yawitch TM, van der Merwe NC, et al. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 2004;110:677–82
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Malan J, Pienaar R, Appfelstaedt J. The role of molecular genetic testing in modern breast health management. SA Fam Pract 2005;47:38–40
   Google Scholar
• Knauer M, Mook S, Rutgers EJT, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655–61
   PubMed Web of Science ®Google Scholar
• Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119:551–8
   PubMed Web of Science ®Google Scholar
• Drukker CA, Bueno-de-Mesquita JM, Retèl VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013;133:929–36
   PubMed Web of Science ®Google Scholar
• Drukker CA, van Tinteren H, Schmidt MK, et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 2014;143:587–92
   PubMed Web of Science ®Google Scholar
• Grant KA, Pienaar FM, Brundyn K, et al. Incorporating microarray assessment of HER2 status in clinical practice supports individualized therapy in early-stage breast cancer. Breast (in press)
   Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18–43
   PubMed Web of Science ®Google Scholar
• Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. Cancer Treat Rev 2014;40:276–84
   PubMed Web of Science ®Google Scholar
• Dabbs DJ, Klein ME, Mohsin SK, et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011;29:4279–85
   PubMed Web of Science ®Google Scholar
• Yamamoto-Ibusuki M, Yamamoto Y, Fu P, et al. Divisional role of quantitative HER2 testing in breast cancer. Breast Cancer 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Park MM, Ebel JJ, Zhao W, Zynger DL. ER and PR immunohistochemistry and HER2 FISH versus Oncotype DX: implications for breast cancer treatment. Breast J 2014;20:37–45
   PubMed Web of Science ®Google Scholar
• Pohl EH, Myburgh EJ, Grant KA, et al. Cost-effective introduction of the 70-gene MammaPrint assay in South Africa and the impact on treatment decision making. Prevention of Prostate, Breast and Cervical Cancer in Africa Congress, 22 July 2014, Windhoek, Namibia
   Google Scholar
• Grant K, Cronje FJ, Botha K, et al. Development of a genetic database resource for monitoring of breast cancer patients at risk of physical and psychological complications. S Afr J Psychiatry 2013;19:96–7
   Web of Science ®Google Scholar
• Phipps AI, Buist DS, Malone KE, et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat 2011;126:671–8
   PubMed Web of Science ®Google Scholar
• Bardia A, Arieas E, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012;131:907–14
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009;27:5312–18
   PubMed Web of Science ®Google Scholar
• Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 2014;46:736–41
   PubMed Web of Science ®Google Scholar
• Ghadirian P, Narod S, Fafard E, et al. Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity. Breast Cancer Res Treat 2009;17:417–22
   Google Scholar
• Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009;136:1039–46
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347–63
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with metabolic syndrome. Diabetes Care 2005;28:1201–3
   PubMed Web of Science ®Google Scholar
• Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35:1171–80
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 2013;39:306–18
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170:265–74
   PubMed Web of Science ®Google Scholar
• Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive decline among older women. Arch Neurol 2009;66:324–8
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 2012;69:741–62
   PubMed Web of Science ®Google Scholar
• Wens I, Dalgas U, Stenager E, Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis – a systematic review. Mult Scler 2013;19:1556–64
   PubMed Web of Science ®Google Scholar
• Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol 2011;25:274–6
   PubMed Web of Science ®Google Scholar
• Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;13:9–19
   PubMed Web of Science ®Google Scholar
• Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 2012;8:729–37
   PubMed Web of Science ®Google Scholar
• Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Current Opinion Rheumatol 2008;20:187–91
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim CH, Sung EJ, et al. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013;62:808–13
   PubMed Web of Science ®Google Scholar
• Calvin AD, Albuquerque FN, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea, inflammation and the metabolic syndrome. Metab Syndr Relat Disord 2009;7:271–7
   PubMed Web of Science ®Google Scholar
• Davis W, van Rensburg SJ, Cronje FJ, et al. The fat mass and obesity-associated FTO rs9939609 polymorphism is associated with elevated homocysteine levels in patients with multiple sclerosis screened for vascular risk factors. Metab Brain Dis 2014;29:409–19
   PubMed Web of Science ®Google Scholar
• Delport D, Schoeman R, van der Merwe N, et al. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C > T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis 2014;29:377–84
   PubMed Web of Science ®Google Scholar
• Lückhoff HK, Van Rensburg SJ, Botha K, et al. The Pro-Inflammatory TNFA -308G > A (rs1800629) Polymorphism is associated with an earlier age at onset in patients with major depressive disorder. J Psychiatry 2014;17:1–6
   Google Scholar
• Lückhoff HK, Brand T, van Velden DP, et al. Clinical relevance of apolipoprotein E genotyping based on a family history of Alzheimer’s disease. Curr Alz Res 2014 (in press)
   Google Scholar
• Nelson MC, Isaacs F, Hassan MS, et al. Prevalence of abnormal blood flow patterns and effects of biochemistry and lifestyle factors on the major neck vessels in patients with Multiple Sclerosis in the Western Cape, South Africa. Med Tech SA 2014;28:26–33
   Google Scholar
• van Velden DP, Kotze MJ, Blackhurst D, et al. Health claims and the benefits of moderate alcohol consumption in relation to genetic profiles. J Wine Res 2011;22:123–9
   Google Scholar
• McIntyre RS, Park KY, Law CWY, et al. The association between conventional antidepressants and the metabolic syndrome. CNS Drugs 2010;24:741–53
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Thiart R. Genetics of dyslipidaemia. CME J 2003;21:399–402
   Google Scholar
• Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia – clinical and pathophysiological features. S Afr Med J 2002;92:892–7
   PubMed Web of Science ®Google Scholar
• Koruk M, Savaş MC, Yilmaz O, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;37:177–82
   PubMed Web of Science ®Google Scholar
• Kruger FC, Daniels C, Kidd M, et al. Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis. S Afr Med J 2010;100:168–71
   PubMed Web of Science ®Google Scholar
• Shiri-Sverdlov R, Wouters K, van Gorp PJ, et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006;44:732–41
   PubMed Web of Science ®Google Scholar
• Zambón D, Quintana M, Mata P, et al. Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 2010;123:267–74
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258:28–47
   PubMed Web of Science ®Google Scholar
• Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis 2011;10:1–7
   Google Scholar
• Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 2008;12:2762–71
   PubMed Web of Science ®Google Scholar
• Kotze MJ, de Villiers WJS, Steyn K, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993;13:1460–8
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Lückhoff HK, Brand T, et al. Apolipoprotein ɛ-4 as a genetic determinant of Alzheimer’s disease heterogeneity. Degener Neurol Neuromuscul (in press)
   Google Scholar
• Woods AG, Sokolowska I, Taurines R, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 2012;16:1184–95
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Langenhoven E, Theart L, et al. Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners. Genet Counselling 1994;5:15–21
   PubMedGoogle Scholar
• Sun X, Nicholas J, Walker A, et al. APOE genotype in the diagnosis of Alzheimer’s disease in patients with cognitive impairment. Am J Alzheimers Dis Other Demen 2012;27:315–20
   PubMed Web of Science ®Google Scholar
• Kotze MJ, Marnewick JL, Kidd M, et al. Assessment of the impact of hereditary factors on biochemical parameters of cardiovascular risk in relation to moderate alcohol consumption. Nutr Aging 2014;2:189–95
   Google Scholar
• Djoussé L, Pankow JS, Arnett DK, et al. Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr 2004;80:1639–44
   PubMed Web of Science ®Google Scholar
• Corella D, Tucker K, Lahoz C, et al. Alcohol drinking determines the effect of the APOE locus on LDL-cholesterol concentrations in men: the Framingham Offspring Study. Am J Clin Nutr 2001;73:736–45
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Martínez R, Fernández-Novoa L, et al. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimers Dis 2012;2012:1-1-37
   Google Scholar
• Frudakis TN, Thomas MJ, Ginjupalli SN, et al. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007;17:695–707
   PubMed Web of Science ®Google Scholar
• Brauch H, Schroth W, Goetz MP, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013;31:176–80
   PubMed Web of Science ®Google Scholar
• Lou DI, Hussmann JA, McBee RM, et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. PNAS 2013;110:19872–7
   PubMed Web of Science ®Google Scholar
• Feero WG. Clinical application of whole-genome sequencing: proceed with care. JAMA 2014;311:1017–19
   PubMed Web of Science ®Google Scholar
• Bansal V, Libiger O, Torkamani A, Schork NJ. Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet 2010;11:773–85
   PubMed Web of Science ®Google Scholar
• Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012;2012:1–11
   PubMedGoogle Scholar
• Tintle N, Aschard H, Hu I, et al. Inflated type I error rates when using aggregation methods to analyze rare variants in the 1000 Genomes Project exon sequencing data in unrelated individuals: summary results from Group 7 at Genetic Analysis Workshop 17. Genet Epidemiol 2011;35:56–60
   Google Scholar
• Lyon GJ, Wang K. Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress. Genome Med 2012;4:1–16
   PubMedGoogle Scholar
• Boland JF, Chung CC, Roberson D, et al. The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet 2013;132:1153–63
   PubMed Web of Science ®Google Scholar
• Jalali Sefid Dashti M, Kotze MJ, van Rensburg SJ, et al. Exome sequencing combined with semantic discovery identifies strong disease-associated candidates in a single case of relapsing remitting multiple sclerosis. BMC Proc 2012;6:P10
   Google Scholar
• O’Rawe J, Jiang T, Sun G, et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 2013;5:1–18
   PubMedGoogle Scholar
• Kotze MJ, de Villiers JNP, Rooney RN, et al. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol Dis 2001;27:44–53
   PubMed Web of Science ®Google Scholar
• De Villiers JNP, Treurnicht FK, Warnich L, et al. Analysis of viral and genetic factors in South African patients with multiple sclerosis. Metab Brain Dis 2006;21:163–9
   PubMed Web of Science ®Google Scholar
• Moremi K, van Rensburg SJ, Fisher LR, et al. Association of an iron-related TMPRSS6 genetic variant c.2207 C > T (rs855791) with functional iron deficiency and its effect on multiple sclerosis risk in the South African population. S Afr J Psychiatry 2013;19:120–1
   Web of Science ®Google Scholar
• Chambers JC, Zhang W, Li Y, et al. Genome-ide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009;41:1170–2
   PubMed Web of Science ®Google Scholar
• van Toorn R, Schoeman JF, Solomons R, et al. Iron status in children with recurrent episodes of tumefactive cerebral demyelination. J Child Neurol 2010;25:1401–7
   PubMed Web of Science ®Google Scholar
• Davis W, de Kock L, Pretorius K, et al. Development of a single nucleotide polymorphism (SNP) knowledge database: ASMT rs4446909, rs598968 and MTHFR rs1801133 as susceptibility alleles for depression. Afr J Psychiatry 2011; Abstract:5
   Google Scholar
• Dewey FE, Chen R, Cordero SP, et al. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet 2011;7:e1002280
   PubMed Web of Science ®Google Scholar
• Lajugie J, Mukhopadhyay R, Schizas M, et al. Complete genome phasing of family quartet by combination of genetic, physical and population-based phasing analysis. PLoS One 2013;8:e64571
   PubMedGoogle Scholar
• Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2007;35:D61–5
   PubMed Web of Science ®Google Scholar
• Chen R, Butte AJ. The reference human genome demonstrates high risk of type 1 diabetes and other disorders. Pac Symp Biocomput 2011:231–42
   PubMedGoogle Scholar
• Kotze MJ, Schorn D, Coetzer P. The impact of genetic testing on life insurance. J Genomics Afr Soc 2004;1:1–11
   Google Scholar
• Hansson MG. Ethics and biobanks. Br J Cancer 2009;100:8–12
   PubMed Web of Science ®Google Scholar
• Cordell S. The biobank as an ethical subject. Health Care Anal 2011;19:282–94
   PubMed Web of Science ®Google Scholar
• Wright GE, Koornhof PG, Adeyemo AA, Tiffin N. Ethical and legal implications of whole genome and whole exome sequencing in African populations. BMC Med Ethics 2013;28:14–21
   Google Scholar
• Choudhury A, Hazelhurst S, Meintjes A, et al. Population-specific common SNPs reflect demographic histories and highlight regions of genomic plasticity with functional relevance. BMC Genomics 2014;15:437
   PubMedGoogle Scholar
• Yu JH, Jamal SM, Tabor HK, Bamshad MJ. Self-guided management of exome and whole-genome sequencing results: changing the results return model. Genet Med 2013;15:684–90
   PubMed Web of Science ®Google Scholar
• Ashley EA, Butte AJ, Wheeler MT, et al. Clinical evaluation incorporating a personal genome. Lancet 2010;375:1525–35
   PubMed Web of Science ®Google Scholar
• Patel CJ, Sivadas A, Tabassum R, et al. Whole genome sequencing in support of wellness and health maintenance. Genome Med 2013;5:1–13
   PubMedGoogle Scholar